Lateral Flow Assays Market

Despite major improvements in sanitation and medicine, the global prevalence of infectious diseases remains high. Although non-communicable diseases are the leading cause of morbidity and mortality, infectious diseases remain a major public health concern across the globe. According to the World Health Organization's Global Tuberculosis Report 2025, tuberculosis (TB) remained the leading infectious disease killer in 2024, with an estimated 10.7 million people falling ill with TB and 1.23 million deaths globally. In 2024, 14.6 million dengue cases and more than 12,000 dengue-related deaths were reported globally, representing the highest number of dengue cases recorded in a 12-month period.

While lateral flow assay (LFA) tests offer advantages such as rapid turnaround time, user-friendliness, and affordability, a major drawback is their variable accuracy and reliability, especially compared with more established laboratory techniques like ELISA or PCR. LFAs often struggle with sensitivity and specificity, particularly when analyte concentrations are near the assay’s detection threshold or when sample-handling procedures are suboptimal. These issues can result in false negatives or false positives, potentially affecting clinical decisions and leading to suboptimal patient outcomes. For example, in tuberculosis screening, some antigen-based LFA tests have exhibited reduced sensitivity in HIV-positive patients, likely due to lower bacterial loads, contributing to missed diagnoses. Likewise, in malaria diagnostics, certain LFA tools have shown diminished ability to detect low-parasite-density cases, which is especially problematic in low-transmission regions or during elimination efforts.

Lateral flow assays (LFAs) have advanced significantly over the past two decades and are now commonly used in point-of-care (POC) and diagnostic settings. While traditionally employed for infectious disease detection, cardiac disease diagnosis, and veterinary testing, their application scope has expanded in recent years. Emerging areas now include saliva-based diagnostics, behavioral health screening, agricultural testing (such as detection of genetically modified organisms and crop quality assessment), biowarfare agent detection (e.g., anthrax), environmental monitoring (for contaminating enzymes in manufacturing facilities), and food microbiology (identifying pathogens like E. coli O157, Salmonella, Listeria, and other spoilage organisms).

Reimbursement challenges have hindered the widespread adoption of lateral flow assay (LFA)-based diagnostic tests in various countries. As healthcare expenditure continues to rise, insurance providers are increasingly scrutinizing the necessity and value of new diagnostic tools. This shift is further influenced by the global transition from traditional fee-for-service models to value-based reimbursement systems. Consequently, diagnostic tests that merely support clinical decision-making without directly influencing treatment pathways often receive insufficient reimbursement, leading to their reduced use or underfunding.